Tech Company Financing Transactions
Novira Therapeutics Funding Round
Novira Therapeutics, based in Doylestown, secured $7.5 million in funding from Versant Ventures.
Transaction Overview
Company Name
Announced On
3/26/2013
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Series A
Investors
Versant Ventures (Gianni Gromo)
Proceeds Purpose
We plan to use these funds to advance development of our hepatitis B virus (HBV) capsid inhibitor lead program toward the clinic and to discover additional HBV drug candidates.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3805 Old Easton Road
Doylestown, PA 18902
USA
Doylestown, PA 18902
USA
Phone
Website
Email Address
Overview
Novira is an antiviral drug discovery company launched in 2009 that is focused on the discovery of novel, first-in-class therapeutics for the treatment of HBV and HIV, two global diseases in need of better therapies. The company is led by seasoned pharmaceutical industry executives with proven records of success in drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christian Schade
Chief Medical Officer
Nathaniel Brown
Chief Scientific Officer
Osvaldo Flores
Browse more venture capital transactions:
Prev: 3/26/2013: Watermark Medical venture capital transaction
Next: 3/26/2013: BA Insight venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs